http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201517899-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b979eed794220ad42d452c5442229eea |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2013-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf53d8d0cb8b7501d0e64f33442cfc17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd56e2dfbec260611d0d08789b0101fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af381c15a44723f19221b70e42125dd5 |
| publicationDate | 2015-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201517899-A |
| titleOfInvention | Use of metformin and sodium butyrate in KRAS gene mutation cancer therapy, pharmaceutical composition and medical kit |
| abstract | A use of metformin and sodium butyrate for the manufacture of a pharmaceutical composition for treating a cancer patient having a K-ras gene mutation, and when the pharmaceutical composition is administered to the cancer patient, the metformin and the sodium butyrate are combined The effect. The invention further discloses a pharmaceutical composition and a medical kit comprising the above two. The use of the present invention, pharmaceutical compositions and medical kits can improve the efficacy of cancer patients with mutations in the K-ras gene. |
| priorityDate | 2013-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 110.